Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia.

× No keyword cloud information.

19 in total

1. Next generation therapy in chronic myeloid leukemia.

Authors: Pranab Kumar Bhattacharya; Upasana Bhattacharya; Rupak Bhattacharya; Ritwik Bhattacharya; Soumyak Bhattacharya; Rupsa Bhattacharya; Dalia Mukherjee; Oindrila Mukherjee; Debasis Mukherjee; Debasis Roy Barman; Soma Das; Anuradha Dey; Ranu Roy Biswas; Surajit Sarkar
Journal: Indian J Hematol Blood Transfus Date: 2012-04-08 Impact factor: 0.900

2. T-cell lymphoproliferative disorder potentially induced by imatinib in a patient with GIST.

Authors: Mareike Verbeek; Falko Fend; Thomas Licht; Christian Meyer zum Büschenfelde; Jens Stollfuss; Christian Peschel; Justus Duyster
Journal: Nat Rev Clin Oncol Date: 2010-02 Impact factor: 66.675

3. CML as Part of Dual Malignancies-A Retrospective Analysis: Possible Mechanisms and Review of Literature.

Authors: Kamal Kant Sahu; Yanamandra Uday; Amanjit Bal; Neelam Varma; Shano Naseem; Alka Khadwal; Gaurav Prakash; S Varma; Pankaj Malhotra
Journal: Indian J Hematol Blood Transfus Date: 2015-11-21 Impact factor: 0.900

4. Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report.

Authors: G Mihaylov; V Varbanova; V Stoeva; T Dikov
Journal: Hippokratia Date: 2016 Jul-Sep Impact factor: 0.471

5. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.

Authors: Dushyant Verma; Hagop Kantarjian; Sara S Strom; Mary Beth Rios; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal: Blood Date: 2011-08-16 Impact factor: 22.113

6. High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.

Authors: Josef Martz; Sarika Jain; Linda T Vahdat; Lihui Qin; Juan Miguel Mosquera; Cristina R Antonescu; Elizabeta C Popa
Journal: J Clin Oncol Date: 2013-02-25 Impact factor: 44.544

7. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.

Authors: Tariq I Mughal; Andrew Schrieber
Journal: Biologics Date: 2010-12-02

Review 8. Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature.

Authors: Yasunobu Sekiguchi; Asami Shimada; Moe Matsuzawa; Hidenori Imai; Mutsumi Wakabayashi; Keiji Sugimoto; Noriko Nakamura; Tomohiro Sawada; Junichi Arita; Norio Komatsu; Masaaki Noguchi
Journal: Turk J Haematol Date: 2015-09 Impact factor: 1.831

9. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors: Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal: Ther Clin Risk Manag Date: 2008-02 Impact factor: 2.423

10. Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report.

Authors: Meng-Jie Jiang; Shan-Shan Weng; Ying Cao; Xiao-Fen Li; Liu-Hong Wang; Jing-Hong Xu; Ying Yuan
Journal: Medicine (Baltimore) Date: 2015-09 Impact factor: 1.817